Wipawee Nittayananta1,2, Aree Kanjanaprapas3, Pratanporn Arirachakaran4,5,6, Kanokporn Pangsomboon3, Hutcha Sriplung7. 1. Excellent Research Laboratory, Phytomedicine and Pharmaceutical Biotechnology Excellence Center, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Hat Yai, Songkhla, Thailand. 2. Natural Product Research Center of Excellence, Faculty of Science, Prince of Songkla University, Hat Yai, Songkhla, Thailand. 3. Department of Stomatology, Faculty of Dentistry, Prince of Songkla University, Hat Yai, Songkhla, Thailand. 4. Department of Oral Medicine, Faculty of Dentistry, Chulalongkorn University, Bangkok, Thailand. 5. Infectious Diseases Clinic, Dental Hospital, Faculty of Dentistry, Chulalongkorn University, Bangkok, Thailand. 6. Dental Center, Bangkok Hospital, Bangkok, Thailand. 7. Epidemiology Unit, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand.
Abstract
BACKGROUND: Previous studies have reported that human immunodeficiency virus (HIV) infection and antiretroviral therapy (ART) can lead to osteoporosis in HIV-infected individuals. However, their effects on alveolar bone are not well established. The objective of this study was to measure the alveolar bone mineral density (BMD) of HIV-infected patients, with and without antiretroviral therapy (ART), in comparison with that of HIV-free individuals, and to determine factors associated with the BMD of alveolar bone. METHODS: A cross-sectional study was performed in non-HIV-infected individuals and HIV-infected individuals, with and without ART. Medical status and clinical data were recorded. Periapical radiographs of maxillary and mandibular right premolars were analysed for changes of alveolar BMD based on HIV/ART status. Other factors associated with the changes of alveolar BMD were explored using a parametric multivariate analysis of covariance (MANCOVA). RESULTS: One-hundred and one HIV-infected individuals receiving ART (age range: 23-57 years; median age 39 years), 58 receiving no ART (age range: 20-59 years; median age 34 years) and 50 HIV-negative individuals (age range: 19-59 years; median age 36 years) were enrolled. Neither HIV status nor use of ART was significantly associated with the changes of alveolar BMD. CONCLUSION: Although osteoporosis has been reported in HIV-infected individuals treated with ART, alveolar BMD does not appear to be changed as a result of the infection, or use of ART.
BACKGROUND: Previous studies have reported that human immunodeficiency virus (HIV) infection and antiretroviral therapy (ART) can lead to osteoporosis in HIV-infected individuals. However, their effects on alveolar bone are not well established. The objective of this study was to measure the alveolar bone mineral density (BMD) of HIV-infected patients, with and without antiretroviral therapy (ART), in comparison with that of HIV-free individuals, and to determine factors associated with the BMD of alveolar bone. METHODS: A cross-sectional study was performed in non-HIV-infected individuals and HIV-infected individuals, with and without ART. Medical status and clinical data were recorded. Periapical radiographs of maxillary and mandibular right premolars were analysed for changes of alveolar BMD based on HIV/ART status. Other factors associated with the changes of alveolar BMD were explored using a parametric multivariate analysis of covariance (MANCOVA). RESULTS: One-hundred and one HIV-infected individuals receiving ART (age range: 23-57 years; median age 39 years), 58 receiving no ART (age range: 20-59 years; median age 34 years) and 50 HIV-negative individuals (age range: 19-59 years; median age 36 years) were enrolled. Neither HIV status nor use of ART was significantly associated with the changes of alveolar BMD. CONCLUSION: Although osteoporosis has been reported in HIV-infected individuals treated with ART, alveolar BMD does not appear to be changed as a result of the infection, or use of ART.
Authors: Alfonso Fausto; Marco Bongiovanni; Paola Cicconi; Laura Menicagli; Emanuela Valentina Ligabò; Sara Melzi; Teresa Bini; Francesco Sardanelli; GianPaolo Cornalba; Antonella d'Arminio Monforte Journal: Bone Date: 2005-12-27 Impact factor: 4.398
Authors: Grace A McComsey; Douglas Kitch; Eric S Daar; Camlin Tierney; Nasreen C Jahed; Pablo Tebas; Laurie Myers; Kathleen Melbourne; Belinda Ha; Paul E Sax Journal: J Infect Dis Date: 2011-06-15 Impact factor: 5.226
Authors: Joel E Gallant; Edwin DeJesus; José R Arribas; Anton L Pozniak; Brian Gazzard; Rafael E Campo; Biao Lu; Damian McColl; Steven Chuck; Jeffrey Enejosa; John J Toole; Andrew K Cheng Journal: N Engl J Med Date: 2006-01-19 Impact factor: 91.245
Authors: Julia H Arnsten; Ruth Freeman; Andrea A Howard; Michelle Floris-Moore; Yungtai Lo; Robert S Klein Journal: AIDS Date: 2007-03-12 Impact factor: 4.177
Authors: Michael T Yin; Chiyuan A Zhang; Donald J McMahon; David C Ferris; Dinaz Irani; Ivelisse Colon; Serge Cremers; Elizabeth Shane Journal: J Clin Endocrinol Metab Date: 2011-11-16 Impact factor: 5.958
Authors: Joel E Gallant; Schlomo Staszewski; Anton L Pozniak; Edwin DeJesus; Jamal M A H Suleiman; Michael D Miller; Dion F Coakley; Biao Lu; John J Toole; Andrew K Cheng Journal: JAMA Date: 2004-07-14 Impact factor: 56.272
Authors: C Amiel; A Ostertag; L Slama; C Baudoin; T N'Guyen; E Lajeunie; L Neit-Ngeilh; W Rozenbaum; M C De Vernejoul Journal: J Bone Miner Res Date: 2003-12-22 Impact factor: 6.741